Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Livzon Pharmaceutical Group ( (HK:1513) ) has provided an announcement.
Livzon Pharmaceutical Group has entered into the 2025 Utilities Supplemental Agreement and the 2025 Service Supplemental Agreement with Livzon MAB to adjust the annual caps for connected transactions. The agreements aim to meet Livzon MAB’s operational needs by increasing the maximum amounts for utilities and services provided by the Group. These transactions are subject to reporting requirements under Hong Kong Listing Rules but are exempt from independent shareholders’ approval.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$37.23 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Average Trading Volume: 882,769
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.09B
Learn more about 1513 stock on TipRanks’ Stock Analysis page.